Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease
Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease
复制标题
DOI：
10.1080/14767058.2018.1438401
复制
发表时间：
2019-08-03
影响因子：
1.8
通讯作者：
Ikeda, Tomoaki
中科院分区：
文献类型：
--
作者：
Tanaka, Kayo;Tanaka, Hiroaki;Ikeda, Tomoaki
背景资料：本研究的目的是评价他达拉非治疗胎儿生长受限（FGR）的效果以及因此使用他达拉非的无心血管疾病孕妇的心功能。材料和方法：我们检查了九名使用他达拉非治疗FGR的无心血管疾病的孕妇。在使用他达拉非之前和之后评估母体心率、收缩压（BP）和超声心动图结果。结果：他达拉非治疗后舒张压较治疗前降低，但差异无统计学意义。使用他达拉非前后超声心动图结果无显著差异。结论：他达拉非对无心血管疾病的妊娠女性无不良影响，由于其不影响母亲的心脏功能，因此认为可接受使用。
Background: The aim of the present study was to evaluate tadalafil for the treatment of fetal growth restriction (FGR) and the cardiac function in pregnant women without cardiovascular disease who used tadalafil for this reason. Materials and methods: We examined nine pregnant women without cardiovascular disease who were using tadalafil to treat FGR. Maternal heart rate, systolic blood pressure (BP), and echocardiographic findings were assessed before and after tadalafil use. Results: Diastolic BP was lower after compared to that before using tadalafil, but the difference was not significant. Echocardiographic findings were not significantly different before and after tadalafil use. Conclusions: Tadalafil did not adversely affect pregnant women without cardiovascular disease and was considered acceptable for use since it did not affect the mother's cardiac function.